Highbridge Capital Management’s Halozyme HALO Stock Holding History

Highbridge Capital Management’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-17,300	Closed	-$301K	–	1769
2017 Q3	$301K	Buy	17,300 +5,800	+50%	+$78.6K	﹤0.01%	1202
2017 Q2	$147K	Buy	+11,500	New	+$154K	﹤0.01%	1148
2016 Q2	–	Sell	-250,400	Closed	-$2.37M	–	1523
2016 Q1	$2.37M	Buy	+250,400	New	+$2.36M	0.04%	467

Other funds holding HALO

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Highbridge Capital Management's HALO Position: Q1 2017 in Review

Highbridge Capital Management sold out of Halozyme (HALO) in Q1 2017, closing a stake of 21,770 shares — an estimated $215K sold.

Highbridge Capital Management first reported a position in HALO in Q2 2013 and held it in 3 quarters. The position peaked at $629K in Q3 2015. 160 funds tracked by Wall St. Rank hold HALO as of Q1 2017.

Highbridge Capital Management reported no remaining Halozyme position as of Q1 2017 after selling out during the quarter.
Highbridge Capital Management sold 21,770 Halozyme shares in Q1 2017, an estimated $215K.
Highbridge Capital Management first reported a position in Halozyme in Q2 2013 and held it in 3 quarters.
Highbridge Capital Management's Halozyme position peaked at $629K in Q3 2015.
160 funds tracked by Wall St. Rank held Halozyme as of Q1 2017.

Based on Highbridge Capital Management's 13F filing for Q1 2017, filed 15 May 2017.